Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Unit 3 B&L > BL 02-25-14 10-11am Immunomodulators - Cohen > Flashcards

BL 02-25-14 10-11am Immunomodulators - Cohen Flashcards

1
Q

Immunomodulation

A

use of drugs (alone or in combo with other maneuvers) to change the function of all or part of the immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Categories of Immunomodulators

A
  1. NSAIDs
  2. Disease-modifying antirheumatic drugs (DMARDs).
  3. Glucocorticoids.
  4. Biological response modifiers.
  5. Tumor-specific monoclonal antibodies.
  6. Other antibodies.
  7. Miscellaneous drugs.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Biological Response Modifiers

A 
- loose class of substances targeted
mostly at cytokines or their receptors, or at cellular communication molecules
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Different kinds of Biological Response Modifiers

A
  • antagonists or agonists
  • may be genetically-engineered receptor antagonists. or cloned, mass-produced normal gene products
  • many are antibodies to various components of the immune/inflammatory system
  • -> stimulate, inhibit, or opsonize (depending on designer’s intentions)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Monoclonal antibodies (mAb) - overview

A
  • Dream manufactoring: can be manufacture under ideal conditions, any quantity can be made, with complete uniformity of product
  • BUT, very expensive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Monoclonal antibodies (mAb) - what are they

A
  • antibodies derived from the progengy of a single B cells, that has been fused with multiple myeloma tumor cells (Hybridoma)
  • resultant hybrid line can grow forever in culture like its tumor parent, but can make the specific antibody of its B cell parent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Murine mAbs

A
  • made from immunized mice

- omab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

-omab

A
  • made from immunized mice

- murine mAbs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

chimeric mAbs

A
  • mAbs engineered at DNA level to have mouse
    VL & VH domains, but human C domains
  • less likely to be recognized by pt’s own immune system
    -ximab
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

-ximab

A
  • chimeric mAbs
  • mAbs engineered at DNA level to have mouse
    VL & VH domains, but human C domains
  • less likely to be recognized by pt’s own immune system
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

humanized mAbs

A
  • mAbs which have only the CDR’s of the V domains are from the mouse
  • zumab
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q
  • zumab
A
  • humanzied mAb

- mAbs which have only the CDR’s of the V domains are from the mouse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

human mAbs

A
  • fully human mAbs (no mouse parts)

- umab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

-umab

A
  • human mAbs (fully human, with no mouse parts)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Targets of mAbs

A
  • Several mAb to TNFalpha
  • glycoprotein IIb/IIIa receptor (platelet aggregation)
  • IL-2 receptor
  • CD11s (LFA-1) [T cell activation]
  • human IgE
  • alpha-4 integrin (lymphocyte migration)
  • IL-12, IL-23
  • IL-6 receptor
  • B-lymphocyte stimulator (BLyS)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Pregnancy & mAbs

A

mAbs are IgG, so will cross placenta

So, PEGylate them - polyethylene glycal (does not cross placenta)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

NK (natural killer) cells - overview

A
  • large granular lymphocytes (LGL)
  • make up 5010% of blood lymphocyte cells
  • killers with mechanisms available similar to those of CTL, but do not have rearranged V(D)J gene and are not thymic-derived
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

NK cells - two tricks

A
  1. a few NK receptors which recognize molecules on surface of “stress” or dysregulated cells (virally-infection or tumor), which they then kill
    - -> part of the innate immune system
  2. NK receptors for Fc end of IgG (FCgammaR), giving them a second antibody-dependent way to interact with target cells = antibody-dependent cell-mediated cytotoxicity (ADCC)
    - -> part of the adaptive immune system
19
Q

ADCC (antibody-dependent cell-meidated cytotoxicity)

A
  • don’t know much about its role in normal immunity
    Used in the case of tumor cells that do NOT express markers that NK cells will recognized via NK receptors
    thus, NK cells need antibody help to recognize & kill such tumor cells
20
Q

Mechanism of ADCC

A
  • IgG antibody binds to the target cell (but can’t kill it)
  • NK cell (LGL) binds to Fc end of the antibody
  • Just like a killer T cell, NK cell is now triggered & delivers lethal signals to the target
  • Target dies by apoptosis

s blood leukocytes can be used; not MHC-restricted like CTL-mediated killing is

21
Q

Ways to use ADCC for treatment

A
  • Many new therapeutic mAbs (for immunopathology & cancer) work by triggering ADCC
22
Q

Passive antibody therapy in cancer

A
  • Uses antibody to tumor-associated antigens

- Several mAbs already available

23
Q

Mechanisms of passive mAb therapy in cancer

A
  • A few activate complement, & tumor is lysed or phagocytosed
  • More often they invoke ADCC

Abs can be tagged w/ poison such as calicheamicin or diphtheria toxin, or a radioisotope (= immunotoxins)

  • -> highly-targeted delivery of toxic moiety
  • May be used as both an imaging & therapeutic drug, depending on which radioisotope is attached.
24
Q

passive mAb therapy in cancer – Targets

A
  • CD20 (non-HL, CLL)
  • CD33 (AML)
  • CD52 (B-CLL)
  • EGFR - HER2
  • VEGF
  • CTLA-4 (melanoma)
  • PD-1 (effector CTL inhibitor)
25
Q

BiTE antibodies for cancer

A

1VL + 1VH for CD3 (signaling component of T cell receptr
PLUS
1VL + 1VH for tumor antigen (CD19)

  • -> grabs onto T cell (activating it)
  • -> grabs onto tumor (brings T cell to tumor so it can kill it)

*No specificity needed here, just pulling them together to make T kill tumor

26
Q

Chimeric antigen receptor (CAR) & cancer

A

Takes T cells from cancer pt & transform with lentivirus vectors with a CAR (chimeric antigen receptor)

CDRs from high affinity mAb (to tumor Ag)
PLUS
chain through T cell membrane 
PLUS
CD3 (activate T cell)

==> gives T cell new receptor

  • on outside = highly specific, high affinity Ab to bind tumor cell
  • on inside = what you need to activate T to become cytotoxic

take out T from cancer patient, engineer, grow up, add back into pt

==> SUPER CHARGED T CELLS

27
Q

Other BRMs - Interleukin-2

A

Used in renal cancer and melanoma treatment with

other agents.

28
Q

Other BRMS - Interferon-gamma

A

Approved to treat chronic granulomatous disease & osteopetrosis.

29
Q

Other BRMS - G-CSF

A

Used to treat lymphomas, leukemias, and in bone
marrow transplantation.
Also as an adjunct in cancer chemotherapy

30
Q

Other BRMS - GM-CSF

A

Used to treat leukemias, and in bone marrow

transplantation.

31
Q

denosumab

A

Human mAb against RANK ligand (RANKL).
For use in certain osteoporosis.
Stimulation of RANK causes osteoclast maturation, which denosumab blocks.

32
Q

IVIg

A

Originally used only in immunodeficiency disease, IVIG is now widely used in a variety of conditions including many autoimmune diseases.
- Stimulated inhibitory receptors on phagocytes

33
Q

Traditional drugs (ex. corticosteroids) vs. BRM

A

Corticosteroids
= many side effects (not suprising)

BRM 
= greater specificity 
= mechanism-based design 
= many side affects (unanticipated)
= not always effective (unanticipated)
= expensive!!!
34
Q

Drugs used in Organ Transplantation

A
  • less needed nowadays to get a perfect match, b/c surgeons rely on highly effective immunosupressive therapy
  • purpose of treatment is to prevent rejection & drugs are very good at doing this
  • thus, not the main problem nowadays; rather, other consequences of these drugs are the prob
    = inherently toxic, can increase cancer risk & risk of opportunistic infection
35
Q

Main drugs in Organ Transplantation

A 
Azathioprine
Mycophenolate mofetil
Glucocorticoids
Cyclosporine-A
Tacrolimus
Sirolimus: (rapamycin)
Anti-thymocyte globulin (ATGAM)
mAbs to CD3 and the IL-2 receptor
Miscellaneous drugs
36
Q

Azathioprine

A
  • decreases DNA synthesis & mRNA transcription

- Gradually being replaced by Mycophenolate mofetil

37
Q

Mycophenolate mofetil

A

Less toxic & same mode of action as azathioprine (decreased DNA synthesis & mRNA transcription)

38
Q

Glucocorticoids

A
  • Essential anti-inflammatories in transplantation
  • Usually start with very high dose, taper ASAP, discontinue if possible
  • High doses can also be used briefly for threatened rejection episodes
39
Q

Cyclosporine-A

A
  • Primarily decreases IL-2 production
  • Thus it is synergistic with glucocorticoids which, by down-regulating macrophage function as APCs, lessen stimulation of T cells
40
Q

Tacrolimus

A
  • Can synergize with cyclosporine-A.

- The combo decreases both synthesis & response to IL-2

41
Q

Sirolimus: (rapamycin)

A
  • New relative of cyclosporine.
  • It binds FKBP-12 as does tacrolimus, but the complex has no effect on calcineurin
  • Instead, inhibits kinase called Target of Rapamycin (mTOR) which is needed for T cell activation.
  • Approved in kidney transplantation.
42
Q

Anti-thymocyte globulin (ATGAM)

A
  • Made in horses,& now rabbits immunized with human thymocytes
  • Useful as a part of regimen to prepare recipients for bone marrow transplantation and in acute organ rejection
43
Q

mAbs to CD3 and the IL-2 receptor

A
  • Both can be gotten humanized, though common one, Muromomab, is simply a mouse mAb against CD3 (the same as the well-known diagnostic monoclonal OKT3)
  • Replacing anti-thymocyte globulin but are expensive
  • Too much anti-CD3 can destroy so many T cells at once that the patient undergoes a “cytokine storm”, something like the flu but 1000 times worse
44
Q

Miscellaneous drugs in organ transplantation

A

Drugs may be necessary for infection control, pain management, nutritional support, etc.

Unit 3 B&L (18 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions